Clinical Trial Update: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for LP002 in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• LP002

Snippet

Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd. | Conditions: Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Phase 2 | Status: UNKNOWN